D-erythro-Sphingosine (synthetic) (Synonyms: (-)Sphingosine, DerythroSphingosine C18) |
رقم الكتالوجGC17591 |
D-إريثرو-سفينجوزين (إريثروسفينجوزين) هو منشط قوي جدًا لكيناز p32.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 123-78-4
Sample solution is provided at 25 µL, 10mM.
D-erythro-sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 value of 8μM[1]. D-erythro-Sphingosine is also a PP2A agonist[2]. D-erythro-sphingosine has been shown to inhibit protein kinase C[3].
D-erythro-sphingosine activated TRPM3 variant containing 1325 aa, independently of PKC inhibition, formation of S1P, or intracellular Ca2+ store depletion[4]. D-erythro-sphingosine lowered the levels of HMG-CoA reductase activity in CHO-K1 cells[5]. D-erythro-sphingosine significantly inhibited mastoparan-, but not Na3VO4-, stimulated arachidonic acid release in PC12 cells. Production of prostaglandin F2α was suppressed by D-erythro-sphingosine (10 μM) in PC12 cells. D-erythro-sphingosine, directly inhibited cytosolic phospholipase A2α activity[6]. A p32-sphingosine-activated protein kinase responded to low concentrations of D-erythro-sphingosine with an initial activation observed at 2.5μM and a peak activity at 10-20μM. This kinase showed a modest specificity for D-erythro-sphingosine over other sphingosine stereoisomers, and a preference for sphingosines over dihydro-sphingosines[1]
D-erythro-sphingosine was identified as one of the most influential factors in ASB-induced nephrotoxicity[7]
References:
[1]. Pushkareva MYu, Bielawska A, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid bases and inhibition by non-esterified fatty acids. Biochem J. 1993;294 ( Pt 3)(Pt 3):699-703.
[2]. Cheng P, Chen K, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015;359(1-2):48-56.
[3]. Pham VT, Joo JE, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-sphingosine. Arch Pharm Res. 2007;30(1):22-27.
[4]. Grimm C, Kraft R, et al. Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected] [published correction appears in Mol Pharmacol. 2005 Apr;67(4):1382]. Mol Pharmacol. 2005;67(3):798-805.
[5]. Pinkerton FD, Kisic A, et al. D-erythro-sphingosine lowers 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Chinese hamster ovary cells. Biochem Biophys Res Commun. 1993;190(1):63-69.
[6]. Nakamura H, Hirabayashi T, et al. Inhibition of arachidonic acid release and cytosolic phospholipase A2 alpha activity by D-erythro-sphingosine. Eur J Pharmacol. 2004;484(1):9-17.
[7]. Xu JD, Xing WM, et al. Metabolic changes in the urine of andrographolide sodium bisulfite-treated rats. Hum Exp Toxicol. 2016;35(2):162-169.
Kinase experiment [1]: | |
Preparation Method | The protein-kinase assay was carried out in a total volume of 50µL containing 5µL of sphingosine (D-erythro-sphingosine) suspension (or ethanol solution), 5µL of other effectors, 20µL Mg2+/ATP solution (100mM Tris/HCl, pH 7.4, 25mM MgCl2, 62.5µM ATP and 62.5µCi/mL [32P]ATP) and 20µL of diluted cytosol (8-12µg of protein per sample). |
Reaction Conditions | 0-100µM D-erythro-sphingosine |
Applications | When D-erythro-sphingosine was added to cytosolic extracts of Jurkat T cells, it caused a concentration-dependent phosphorylation of a p32 protein, suggesting that a p32-sphingosine-activated protein kinase was being activated. D-erythro-Sphingosine caused an approx.4-fold increase in p32 phosphorylation, with maximal effects observed at a concentration of 10µM of sphingosine. The EC50 for D-erythro-sphingosine was 8µM. |
Cell experiment [2]: | |
Cell lines | HEK293 cells |
Preparation Method | D-erythro-Sphingosine were diluted from 20mM stock solutions in ethanol. |
Reaction Conditions | 20µM D-erythro-Sphingosine |
Applications | Extracellular application of D-erythro-Sphingosine induced an increase in [Ca2+]i in TRPM3-transfected HEK293 cells within 20 to 30s after start of application. In fura-2 quench experiments using 200µM Mn2+, the spontaneous activity of TRPM3-transfected HEK293 cells was enhanced after application of D-erythro-Sphingosine. The concentration of D-erythro-Sphingosine for half-maximal activation of TRPM3 was 12µM obtained from increases in [Ca2+]i. Application of D-erythro-Sphingosine as well as application of hypotonic extracellular solution each produced increases in [Ca2+]i with comparable amplitudes in individual cells. |
References: |
Cas No. | 123-78-4 | SDF | |
المرادفات | (-)Sphingosine, DerythroSphingosine C18 | ||
Chemical Name | (2S,3R,E)-2-aminooctadec-4-ene-1,3-diol | ||
Canonical SMILES | O[C@H](/C=C/CCCCCCCCCCCCC)[C@H](CO)N | ||
Formula | C18H37NO2 | M.Wt | 299.5 |
الذوبان | ≥ 14.9mg/mL in Ethanol | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.3389 mL | 16.6945 mL | 33.389 mL |
5 mM | 0.6678 mL | 3.3389 mL | 6.6778 mL |
10 mM | 0.3339 mL | 1.6694 mL | 3.3389 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *